Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

<p>Table S2</p>

保存先:

書誌詳細
第一著者:	Yun-Guang Hong (14960966) (author)
その他の著者:	Zhigang Yang (14960969) (author), Yan Chen (14960972) (author), Tian Liu (14960975) (author), Yuyuan Zheng (14960978) (author), Chun Zhou (14960981) (author), Guo-Cai Wu (14960984) (author), Yinhui Chen (14960987) (author), Juan Xia (14960990) (author), Ruiting Wen (14960993) (author), Wenxin Liu (14960996) (author), Yi Zhao (14960999) (author), Jin Chen (14961002) (author), Xiangwei Gao (14961005) (author), Zhanghui Chen (14961008) (author)
出版事項:	2025
主題:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
著者:: Amir T. Fathi (15313195)
出版事項: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
著者:: Amir T. Fathi (15313195)
出版事項: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
著者:: Smruthy Sivakumar (15053536)
出版事項: (2025)

Supplementary Tables from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
著者:: Xiangyu Zeng (17314920)
出版事項: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
著者:: Zev A. Wainberg (15047031)
出版事項: (2025)

Figure S1 from Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
著者:: Jeffrey D. Mandell (14963909)
出版事項: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
著者:: Nicolas A. Giraldo (15050937)
出版事項: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
著者:: Nicolas A. Giraldo (15050937)
出版事項: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
著者:: Nicolas A. Giraldo (15050937)
出版事項: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
著者:: Nicolas A. Giraldo (15050937)
出版事項: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
著者:: Nicolas A. Giraldo (15050937)
出版事項: (2025)

Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
著者:: Nicolas A. Giraldo (15050937)
出版事項: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
著者:: Yufang Bao (15386826)
出版事項: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
著者:: Yufang Bao (15386826)
出版事項: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
著者:: Yufang Bao (15386826)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_vs14dnoh0dhoa2b4o99c458042